AFT Pharmaceuticals revised earnings guidance for the year to 31 March 2021 following a number of COVID-19 related delays to licensing negotiations and disruptions to the company's global supply and distribution networks. AFT expects revenue for the 2021 financial year to be around $110 million, representing an uplift on the prior year's $105.6 million. Operating profit for the period is expected to be between $9 million and $11 million, compared with the prior year's equivalent figure of $11.4 million, lower than the guidance affirmed in November 2020 of $14 million to $18 million.